The major research goal of CTID is to address the unmet need for pediatric-specific immune management by performing state-of-the-art translational and clinical research directed at achieving immune tolerance. Developing strategies to induce immune tolerance is widely recognized as the most pressing goal for solid organ transplant, for BMT and for autoimmune diseases. Immune tolerance would allow acceptance of solid organ allografts without the need for lifelong immunosuppression. It would allow widespread use of BMT without the risk of GvHD. It would cure patients with autoimmune diseases without the requirement of complex, life-long medication regimens. The goals of CTID are to:

  • Develop new treatments for children undergoing organ or bone marrow transplantation and for those with autoimmune disorders.
  • Identify biomarkers and genetic traits associated with these diseases, allowing for improved risk stratification and personalized therapies.
  • Allow Children’s to distinguish itself as a preferred destination for children undergoing transplantation and for those with autoimmune disorders.

The vision of CTID is to build a flagship center for translational immunology-based research in children with specific emphasis on transplantation and immune-tolerance-induction.

The CTID will facilitate the development of novel immunologic therapies for children undergoing solid organ transplant, bone marrow transplant and those with autoimmune diseases. It will allow Children’s Healthcare of Atlanta to distinguish itself as a preferred treatment center for children requiring complex immunological management and immune-based therapies